A test in rats has shown that combining varenicline, bupropion, and an indirect glycine agonist (such as ORG-24598) could be beneficial for treatment of alcohol use disorder.[2]
Schizophrenia
Studies have shown that glycine re-uptake inhibitors selective for the type 1 transporter may be useful for the treatment of certain schizophrenia symptoms.[3][4]
^Chue, Pierre (2013). “Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: focus on the glycine transporter 1 (GlyT1)”. Current Pharmaceutical Design. 19 (7): 1311–1320. doi:10.2174/138161213804805766. ISSN1873-4286. PMID23194655.
^Javitt, Daniel C. (July 2002). “Glycine modulators in schizophrenia”. Current Opinion in Investigational Drugs. 3 (7): 1067–1072. ISSN1472-4472. PMID12186269.